Table VI.

Main results of univariate (UVA) and multivariate analysis (MVA) of overall survival in patients with therapy-related acute myeloid leukemia

	UVA	MVA
	P	P	HR	95% CI
Age at diagnosis: ≤60 vs. >60 years	<0.001	<0.001	2.238	1.551–3.228
Performance status: 0–1 vs. ≥2	<0.001	0.010	1.569	1.115–2.208
Platelet (×103/μL): ≥30 vs. <30	0.001	<0.001	1.717	1.303–2.263
Karyotype: favorable vs. non-favorable	<0.001	0.003	4.558	1.650–12.589
FLT3-ITD mutation: pos vs. neg	0.488
NPM1 mutation: pos vs. neg	0.963
Response*: CRp or CR vs. non-CRp	<0.001	<0.001	2.840	2.106–3.830
Response*: CR vs. non-CR	<0.001	<0.001	1.923	1.431–2.585
Ara-C-based vs. non-Ara-C-based	<0.001	0.126	1.347	0.920–1.972
HMA-based vs. non-HMA-based	<0.001	0.401	0.863	0.613–1.217
Low intensity chemotherapy vs. other	0.521
Presence of AHD: pos vs. neg	0.525
ASCT vs. non-ASCT	<0.001	0.171	0.625	0.319–1.224

Abbreviations: UVA, univariate analysis; MVA, multivariate analysis; HR, hazard ratio; CI, confidence interval; CR, complete response; CRp, complete response with incomplete platelet recovery; HMA, hypomethylating agent; AHD, antecedent history of myelodysplasia; ASCT, allogeneic stem cell transplantation.

^*CRp and CR were calculated individually for MVA. CRp was used as a variable to describe other MVA results.